ITCI - BioXcel Therapeutics: AI-Focused Biopharmaceutical Player For 2020
Today, we will study why BioXcel Therapeutics (BTAI) is risky but attractive in 2020.
Company overview
BioXcel Therapeutics is a clinical-stage biopharmaceutical company focused on deploying AI (artificial intelligence) and machine learning to develop drugs across neurology and immuno-oncology. The company is leveraging AI to reduce cost and time for drug development. BioXcel Therapeutics is leveraging AI to identify new uses for previously approved drugs and clinically validated drug targets.
BioXcel Therapeutics' most advanced R&D programs involve a selective ?2a Adrenergic Receptor Agonist, BXCL501 for neurological and psychiatric disorders and DPP 8/9 &